Status | Study |
RECRUITING |
Study Name: A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN) Condition: Prurigo Date: 2023-01-25 Interventions: Ruxolitinib cream 1.5% twice daily (BID) during the vehicle controlled (DBVC)and open label treatment period (OLE). |
Completed |
Study Name: A Randomized Placebo-Controlled Study of the Neurokinin-1 (NK1) Receptor Antagonist Serlopitant Prurigo Nodularis (PN) Condition: Prurigo Nodularis Date: 2014-07-14 Interventions: Drug: serlopitant NK1 receptor |
Active, not recruiting |
Study Name: Open Label Extension Study of Nalbuphine HCl ER in Patients With Prurigo Nodularis Condition: Prurigo Nodularis Nodularis Prurigo Date: 2014-06-24 Interventions: Drug: nalbuphine HCl ER 90 mg BID |
Completed |
Study Name: Study of Nalbuphine HCl ER Tablets in Patients With Prurigo Nodularis Condition: Prurigo Nodularis Nodularis Prurigo Date: 2014-06-24 Interventions: Drug: nalbuphine HCl ER tablets 90 mg BID |
Completed |
Study Name: Topical Aprepitant in Prurigo Patients Condition: Pruritus Date: 2013-09-18 Interventions: Drug: Aprepitant Aprepitant ge |
Not yet recruiting |
Study Name: Dapsone Prurigo Study Condition: Lichen Simples Chronicus and Prurigo Date: 2013-06-03 Interventions: Drug: Dapsone gel - verum Other Name: aczone gel |
Completed |
Study Name: Safety and Efficacy of CC-10004 for Prurigo Nodularis Condition: Prurigo Nodularis Date: 2009-03-23 Interventions: Drug: CC-10004 30mg,oral medication, BID, for 24 weeks (60mg total DAILY) |
Completed |
Study Name: Effectiveness of the Selective Serotonin Reuptake Inhibitor,Citalopram (Cipralex), in Prurigo Nodularis Condition: Prurigo Nodularis Date: 2007-09-19 Interventions: Drug: citalopram (cipralex) 10-20 mg/day, for 12 weeks. |
Completed |
Study Name: Evaluation of the Antipruritic Effect of Elidel (Pimecrolimus) in Non-atopic Pruritic Disease Condition: Prurigo Nodularis Date: 2007-07-26 Interventions: Drug: Pimecrolimus twice daily |